Genome-wide association study evaluating single-nucleotide polymorphisms and outcomes in patients with advanced stage serous ovarian or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study

Published:September 19, 2017DOI:


      • GWAS may identity single nucleotide polymorphisms (SNPs) associated with survival.
      • This GWAS study failed to identify SNPs associated with PFS or OS.
      • Larger GWAS analyses may prove more insightful.



      This study evaluated single nucleotide polymorphisms (SNPs) associated with progression free (PFS) and overall survival (OS) in patients with advanced stage serous EOC.


      Patients enrolled in GOG-172 and 182 who provided specimens for translational research and consent were included. Germline DNA was evaluated with the Illumina's HumanOMNI1-Quad beadchips and scanned using Illumina's iScan optical imaging system. SNPs with allele frequency > 0.05 and genotyping rate > 0.98 were included. Analysis of SNPs for PFS and OS was done using Cox regression. Statistical significance was determined using Bonferroni corrected p-values with genomic control adjustment.


      The initial GWAS analysis included 1,124,677 markers in 396 patients. To obtain the final data set, quality control checks were performed and limited to serous tumors and self-identified Caucasian race. In total 636,555 SNPs and 289 patients passed all the filters. The pre-specified statistical level of significance was 7.855e−08. No SNPs met this criteria for PFS or OS, however, two SNPs were close to significance (rs10899426 p-2.144e08) (rs6256 p-9.774e−07) for PFS and 2 different SNPs were identified (rs295315 p-7.536e07; rs17693104 p-7.734e07) which were close to significance for OS.


      Using the pre-specified level of significance of 1 × 10−08, we did not identify any SNPs of statistical significance for OS or PFS, however several were close. The SNP's identified in this GWAS study will require validation and these preliminary findings may lead to identification of novel pathways and biomarkers.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Gynecologic Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Reis L.A.G.
        E.M. Kosary C.L. SEER Cancer Statistics Review, 1975–2001. 2001
        • Winter 3rd, W.E.
        • et al.
        Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study.
        J. Clin. Oncol. 2007; 25: 3621-3627
        • Hamilton C.A.
        • et al.
        The impact of disease distribution on survival in patients with stage III epithelial ovarian cancer cytoreduced to microscopic residual: a Gynecologic Oncology Group study.
        Gynecol. Oncol. 2011; 122: 521-526
        • Bookman M.A.
        Extending the platinum-free interval in recurrent ovarian cancer: the role of topotecan in second-line chemotherapy.
        Oncologist. 1999; 4: 87-94
        • Markman M.
        • et al.
        Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin.
        J. Clin. Oncol. 1991; 9: 389-393
        • Gore M.E.
        • et al.
        Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds.
        Gynecol. Oncol. 1990; 36: 207-211
        • Colombo N.
        • et al.
        Randomized, open-label, phase III study comparing patupilone (EPO906) with pegylated liposomal doxorubicin in platinum-refractory or -resistant patients with recurrent epithelial ovarian, primary fallopian tube, or primary peritoneal cancer.
        J. Clin. Oncol. 2012; 30: 3841-3847
        • Agarwal R.
        • Kaye S.B.
        Ovarian cancer: strategies for overcoming resistance to chemotherapy.
        Nat. Rev. Cancer. 2003; 3: 502-516
        • Borst P.
        • Rottenberg S.
        • Jonkers J.
        How do real tumors become resistant to cisplatin?.
        Cell Cycle. 2008; 7: 1353-1359
        • Fojo T.
        • Bates S.
        Strategies for reversing drug resistance.
        Oncogene. 2003; 22: 7512-7523
        • Stewart D.J.
        Mechanisms of resistance to cisplatin and carboplatin.
        Crit. Rev. Oncol. Hematol. 2007; 63: 12-31
        • Rabik C.A.
        • Dolan M.E.
        Molecular mechanisms of resistance and toxicity associated with platinating agents.
        Cancer Treat. Rev. 2007; 33: 9-23
        • Jayson G.C.
        • et al.
        Ovarian cancer.
        Lancet. 2014; 384: 1376-1388
        • Kuchenbaecker K.B.
        • et al.
        Identification of six new susceptibility loci for invasive epithelial ovarian cancer.
        Nat. Genet. 2015; 47: 164-171
        • Kar S.P.
        • et al.
        Genome-wide meta-analyses of breast, ovarian, and prostate cancer association studies identify multiple new susceptibility loci shared by at least two cancer types.
        Cancer Discov. 2016; 6: 1052-1067
        • Bolton K.L.
        • et al.
        Common variants at 19p13 are associated with susceptibility to ovarian cancer.
        Nat. Genet. 2010; 42: 880-884
        • Johnatty S.E.
        • et al.
        Genome-wide analysis identifies novel loci associated with ovarian cancer outcomes: findings from the ovarian cancer association consortium.
        Clin. Cancer Res. 2015; 21: 5264-5276
        • Armstrong D.K.
        • et al.
        Intraperitoneal cisplatin and paclitaxel in ovarian cancer.
        N. Engl. J. Med. 2006; 354: 34-43
        • Bookman M.A.
        • et al.
        Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a phase III trial of the Gynecologic Cancer Intergroup.
        J. Clin. Oncol. 2009; 27: 1419-1425
        • O'Donnell P.H.
        • et al.
        Identification of novel germline polymorphisms governing capecitabine sensitivity.
        Cancer. 2012; 118: 4063-4073
        • Maes M.
        • et al.
        Coenzyme Q10 deficiency in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is related to fatigue, autonomic and neurocognitive symptoms and is another risk factor explaining the early mortality in ME/CFS due to cardiovascular disorder.
        Neuro Endocrinol. Lett. 2009; 30: 470-476
        • Au A.Y.
        • et al.
        PTH mutation with primary hyperparathyroidism and undetectable intact PTH.
        N. Engl. J. Med. 2008; 359: 1184-1186
        • Mahmoudi T.
        • et al.
        Parathyroid hormone gene rs6256 and calcium sensing receptor gene rs1801725 variants are not associated with susceptibility to colorectal cancer in Iran.
        Asian Pac. J. Cancer Prev. 2014; 15: 6035-6039
        • Kapur K.
        • et al.
        Genome-wide meta-analysis for serum calcium identifies significantly associated SNPs near the calcium-sensing receptor (CASR) gene.
        PLoS Genet. 2010; 6e1001035
        • Furuta N.
        • et al.
        Reduced expression of BTBD10 in anterior horn cells with Golgi fragmentation and pTDP-43-positive inclusions in patients with sporadic amyotrophic lateral sclerosis.
        Neuropathology. 2013; 33: 397-404
        • Rodriguez-Blanco J.
        • et al.
        The hedgehog processing pathway is required for NSCLC growth and survival.
        Oncogene. 2013; 32: 2335-2345
        • Kamal M.
        • et al.
        Loss of CSMD1 expression is associated with high tumour grade and poor survival in invasive ductal breast carcinoma.
        Breast Cancer Res. Treat. 2010; 121: 555-563
        • Yumrutas O.
        • et al.
        The role of the UTS2 gene polymorphisms and plasma urotensin-II levels in breast cancer.
        Tumour Biol. 2015; 36: 4427-4432
        • Kratochvilova K.
        • et al.
        Tumor suppressor candidate 3 (TUSC3) prevents the epithelial-to-mesenchymal transition and inhibits tumor growth by modulating the endoplasmic reticulum stress response in ovarian cancer cells.
        Int. J. Cancer. 2015; 137: 1330-1340
        • Phelan C.M.
        • et al.
        Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer.
        Nat. Genet. 2017; 49: 680-691
        • Amos C.I.
        • et al.
        The OncoArray Consortium: a network for understanding the genetic architecture of common cancers.
        Cancer Epidemiol. Biomark. Prev. 2017; 26: 126-135
      1. Analysis and sample information courtesy of the Ovarian Cancer Association Consortium (OCAC).